Nicolino Ruperto

Q: What Schools Are Affiliated With Nicolino Ruperto

Nicolino Ruperto is affiliated with the following schools: University of California, Berkeley, Stanford University

Nicolino Ruperto's AcademicInfluence.com Rankings

Nicolino Ruperto

Computer Science

#8532

World Rank

#8969

Historical Rank

Computational Linguistics

#1916

World Rank

#1936

Historical Rank

Machine Learning

#3515

World Rank

#3558

Historical Rank

Artificial Intelligence

#3822

World Rank

#3877

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Nicolino Ruperto's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Nicolino Ruperto Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Nicolino Ruperto's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria (2010) (1094)
Preliminary definition of improvement in juvenile arthritis. (1997) (1068)
EULAR/PReS endorsed consensus criteria* for the classification of childhood vasculitides (2005) (754)
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features (2011) (754)
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. (2012) (702)
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. (2012) (610)
Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. (2004) (606)
Development and validation of a composite disease activity score for juvenile idiopathic arthritis. (2009) (578)
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative (2016) (486)
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial (2008) (414)
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. (2005) (400)
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. (2007) (377)
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis (2011) (368)
A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. (2004) (357)
Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. (2001) (354)
Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review (2012) (343)
Localized scleroderma in childhood is not just a skin disease. (2005) (303)
Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients (2014) (293)
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. (2008) (264)
Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. (2009) (243)
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial (2014) (238)
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis (2016) (236)
The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry (2013) (228)
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus (2018) (219)
International consensus on preliminary definitions of improvement in adult and juvenile myositis. (2004) (218)
Classification criteria for autoinflammatory recurrent fevers (2019) (216)
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. (2003) (213)
Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. (2010) (211)
Treating juvenile idiopathic arthritis to target: recommendations of an international task force (2018) (209)
Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. (2016) (206)
Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. (2010) (205)
Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers (2015) (203)
Long‐term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients (2010) (202)
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation (2010) (198)
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. (2012) (185)
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. (2012) (173)
Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry (2014) (167)
The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. (2007) (163)
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial (2016) (153)
Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. (2003) (152)
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report (2011) (152)
An International registry on Autoinflammatory diseases: the Eurofever experience (2012) (151)
International consensus for a definition of disease flare in lupus (2011) (149)
Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. (2011) (149)
International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. (2005) (147)
The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry (2016) (146)
Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO) (2011) (143)
Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. (2005) (141)
An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis (2011) (141)
The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. (2008) (140)
Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. (2007) (133)
Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. (1997) (129)
A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. (2006) (127)
Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study. (2006) (122)
Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. (2010) (120)
Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension (2009) (119)
Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study (2013) (114)
Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Three‐Variable Juvenile Arthritis Disease Activity Score (2014) (113)
Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes (2013) (113)
Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. (2008) (112)
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis (2010) (112)
Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study (2012) (110)
The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (109)
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis (2013) (108)
Correlation between conventional disease activity measures in juvenile chronic arthritis (1997) (106)
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. (2004) (105)
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis (2012) (104)
Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome. (1997) (104)
Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate (1998) (102)
The Brazilian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (102)
Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children (2013) (99)
Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis (2014) (98)
International research networks in pediatric rheumatology: the PRINTO perspective (2004) (98)
Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab (2016) (97)
Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study (2018) (96)
The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry (2018) (95)
Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. (2007) (94)
Clinical features of childhood granulomatosis with polyangiitis (wegener’s granulomatosis) (2014) (90)
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. (2019) (88)
A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. (2005) (87)
Abatacept improves health‐related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis (2010) (85)
Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. (2007) (83)
The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. (2005) (83)
Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis. (2006) (80)
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial (2017) (80)
Outcome in juvenile onset systemic lupus erythematosus (2005) (80)
The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis (2010) (79)
Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score (2013) (77)
The British version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (76)
Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. (1999) (75)
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative In (2017) (75)
The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement. (2006) (74)
Update on outcome assessment in myositis (2018) (73)
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium (2015) (73)
Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis (2012) (71)
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology (2018) (70)
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study (2012) (69)
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial (2020) (68)
Review: Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? (2007) (67)
Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. (2008) (67)
The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (66)
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis (2016) (66)
The Turkish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (66)
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries (2018) (65)
Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. (2006) (65)
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis (2019) (65)
Catch‐Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial (2015) (65)
Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. (2008) (65)
Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis (2007) (64)
The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. (1999) (62)
Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis (2010) (62)
Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. (2010) (59)
Long‐Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years (2015) (58)
Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group. (1996) (57)
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis (2017) (57)
A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) (2011) (57)
Responsiveness of clinical measures in children with oligoarticular juvenile chronic arthritis. (1999) (57)
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial (2010) (56)
Factors affecting the efficacy of intraarticular corticosteroid injection of knees in juvenile idiopathic arthritis. (2001) (56)
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials (2018) (55)
Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis (2015) (54)
Performance of Different Diagnostic Criteria for Familial Mediterranean Fever in Children with Periodic Fevers: Results from a Multicenter International Registry (2016) (54)
The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (53)
A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus (2011) (53)
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study (2017) (53)
Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. (2006) (51)
A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry (2017) (50)
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. (2011) (49)
Consensus procedures and their role in pediatric rheumatology (2008) (49)
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. (2001) (49)
IgA nephropathy and Henoch-Schonlein syndrome occurring in the same patient. (1996) (48)
Validation of Relapse Risk Biomarkers for Routine Use in Patients With Juvenile Idiopathic Arthritis (2014) (48)
Use of unlabelled and off licence drugs in children. A European paediatric rule is needed to protect children. (2000) (47)
Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. (2011) (46)
Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis (2017) (46)
A national cohort study on pediatric Behçet’s disease: cross-sectional data from an Italian registry (2017) (46)
Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. (1995) (46)
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome (2017) (46)
Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. (2009) (45)
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy (2017) (45)
Responsiveness of outcome measures in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. (1999) (44)
Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept (2013) (43)
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis (2005) (43)
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial (2017) (42)
Discordance between physician's and parent's global assessments in juvenile idiopathic arthritis. (2007) (42)
Development and Testing of Reduced Joint Counts in Juvenile Idiopathic Arthritis (2009) (40)
Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. (1993) (39)
Physicians' and parents' ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis. (2007) (39)
The Eurofever Project: towards better care for autoinflammatory diseases (2011) (38)
Advances from clinical trials in juvenile idiopathic arthritis (2013) (38)
Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases (2019) (38)
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis (2012) (38)
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept (2016) (36)
Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus. (2008) (36)
The Swedish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (36)
Juvenile idiopathic arthritis and malignancy. (2014) (36)
A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis. (2010) (36)
Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis (2016) (35)
The French version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (35)
Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. (1999) (35)
Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis (2018) (35)
Biological classification of childhood arthritis: roadmap to a molecular nomenclature (2021) (35)
Chronic recurrent multifocal osteomyelitis with unusual features (1995) (34)
2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension (2008) (33)
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis (2017) (33)
The Norwegian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (33)
Impact of the European paediatric legislation in paediatric rheumatology: past, present and future (2013) (32)
Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus. (1998) (32)
Juvenile idiopathic arthritis (2022) (31)
Review: The Paediatric Rheumatology International Trials Organization (PRINTO) (2007) (31)
Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey (2010) (30)
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop (2019) (30)
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial (2021) (29)
PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatric-rheumatology.printo.it (2005) (29)
Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. (2003) (29)
Functional ability and physical and psychosocial well-being of hypermobile schoolchildren. (2004) (28)
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. (2020) (28)
Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials. (1996) (28)
A148: A Multi‐Center, Double‐Blind, Randomized‐Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results (2014) (27)
Current and future perspectives in the management of juvenile idiopathic arthritis. (2018) (27)
Quality of life in juvenile idiopathic arthritis patients compared to healthy children (2001) (27)
Criteria to define response to therapy in paediatric rheumatic diseases (2011) (27)
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria—methodological aspects (2017) (25)
TOCILIZUMAB IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: EFFICACY DATA FROM THE PLACEBO-CONTROLLED 12-WEEK PART OF THE PHASE III TENDER TRIAL (2011) (25)
Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis. (2005) (25)
An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA) (2018) (25)
Factors associated with response to methotrexate in systemic‐onset juvenile chronic arthritis (1994) (25)
Development and initial validation of composite parent‐ and child‐centered disease assessment indices for juvenile idiopathic arthritis (2011) (24)
Emerging drugs to treat juvenile idiopathic arthritis (2011) (24)
The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial (2010) (24)
Clinical assessment in juvenile dermatomyositis (2006) (24)
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee (2020) (23)
The Danish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (23)
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Co (2017) (23)
A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities (2017) (22)
Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data (2011) (22)
Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind (2018) (22)
The Finnish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (22)
The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. (2018) (21)
Current Medical Treatments for Juvenile Idiopathic Arthritis (2011) (21)
Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis (2007) (20)
2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) (2008) (20)
Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis (1995) (20)
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial (2019) (20)
The European Spanish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (20)
Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus (2013) (19)
The Portuguese version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (19)
Pediatric rheumatology: JIA, treatment and possible risk of malignancies (2011) (19)
Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. (2012) (18)
Measuring Disease Damage and Its Severity in Childhood‐Onset Systemic Lupus Erythematosus (2018) (18)
Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases (2012) (18)
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‐Label, Active‐Treatment Extension Study (2020) (17)
A Phase II Study to Evaluate Dosing and Preliminary Safety and Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features (2012) (17)
Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities (2018) (16)
The Belgian-Flemish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (16)
A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians (2011) (16)
FRI0328 Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from tender, a phase 3 clinical trial (2013) (16)
A Consensus Hybrid Definition Using a Conjoint Analysis Is the Proposed As Response Criteria for Minimal and Moderate Improvement for Adult Polymyositis and Dermatomyositis Clincal Trials. (2014) (15)
Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care (2018) (15)
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients (2019) (14)
Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis (2021) (14)
Weighting improves the information provided by joint counts on the severity of arthritis and its impact on patients' well-being in juvenile idiopathic arthritis. (2006) (14)
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study (2012) (14)
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept (2020) (13)
American College of Rheumatology Provisional Criteria for Global Flares in Childhood‐Onset Systemic Lupus Erythematosus (2018) (13)
The European network for care of children with paediatric rheumatic diseases: care across borders. (2019) (13)
An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor–associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome (2018) (13)
Toward the Development of New Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis (2012) (13)
Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study (2020) (12)
Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial (2020) (12)
Treatment of juvenile idiopathic arthritis: what's new? (2019) (12)
Does removal of aids/devices and help make a difference in the Childhood Health Assessment Questionnaire disability index? (2009) (12)
The Greek version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (12)
Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis (2008) (11)
Recent advances in quantitative assessment of juvenile idiopathic arthritis (2012) (11)
Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis (2019) (11)
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results (2020) (11)
Comparison of safety, efficacy and pharmacokinetics for 3 and 6 mg/kg infliximab plus methotrexate therapy in JRA patients (2005) (10)
A Meta‐Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis (2016) (10)
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis (2021) (10)
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin‐1 Mediated Autoinflammatory Diseases: Cryopyrin‐Associated Periodic Syndromes, Tumour Necrosis Factor Receptor‐Associated Periodic Syndrome, Mevalonate Kinase Deficiency, an (2022) (10)
American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood‐Onset Systemic Lupus Erythematosus (2019) (10)
The Serbian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (10)
OP0291 TOFACITINIB FOR THE TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: RESULTS OF A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED WITHDRAWAL STUDY (2020) (10)
A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis (2014) (9)
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, an (2022) (9)
OP0059 A Randomized Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine Versus Prednisone Plus Methotrexate (2013) (9)
Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis (2014) (9)
The Korean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (9)
PReS-FINAL-2184: A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate (2013) (9)
Development and validation of a preliminary definition of minimal disease activity in juvenile idiopathic arthritis (2008) (9)
INSAID variant classification and Eurofever criteria guide optimal treatment strategy in patients with TRAPS: data from the Eurofever registry. (2020) (9)
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial (2022) (9)
Specialty training and distribution of work effort among US American College of Rheumatology members caring for children with rheumatic disease. (1997) (9)
Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use (2021) (9)
A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: 2‐Year Data From CHERISH (2014) (9)
The Mexican version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (9)
The Hungarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (8)
The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (8)
A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study (2014) (8)
Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative (2017) (8)
Wegener granulomatosis and childhood Takayasu arteritis : Ankara 2008 . Part II : Final classifi cation criteria (2010) (8)
The Hebrew version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (8)
Frequency of Radiographic Damage and Progression in Individual Joints in Children With Juvenile Idiopathic Arthritis (2014) (8)
Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial (2018) (8)
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison (2021) (8)
Extrapolation or controlled trials in paediatrics: the current dilemma (2017) (8)
The PRINTO /PRES international website for families of children with rheumatic diseases (2004) (8)
SP0110 European Initiative in Pediatric Rheumatology. the Example of the Paediatric Rheumatology International Trials Organisation (PRINTO) (2014) (8)
Macrophage activation syndrome (MAS) in juvenile systemic lupus erythematosus (JSLE): an underrecognized complication? (2008) (8)
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis (2021) (8)
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open‐Label, Randomized, Bayesian Noninferiority Trial (2021) (8)
The Polish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (8)
Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study (2011) (8)
The Swiss German and Swiss French versions of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (7)
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. (2019) (7)
The Argentinian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (7)
Preliminary classification criteria for systemic sclerosis in children. (2005) (7)
Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization (2008) (7)
A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis (2020) (6)
The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (6)
PReS-FINAL-2188: Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study (2013) (6)
Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials (2020) (6)
The Russian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (6)
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis (2020) (6)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one (2017) (6)
OP0215 Subcutaneous Abatacept in Patients with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response To Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety (2016) (6)
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate (2020) (6)
Disease activity, overweight, physical activity and screen time in a cohort of patients with juvenile idiopathic arthritis. (2018) (6)
The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (6)
[The Schönlein-Henoch syndrome with severe multisystemic involvement]. (1993) (6)
Efficacy and Safety of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: 2-Year Data From a Phase III Clinical Trial (2011) (6)
Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis (2011) (5)
FRI0181 THE PLUTO STUDY: INTRAVENOUS BELIMUMAB IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS (2019) (5)
The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (5)
The validated PRINTO core set and definition of improvement for juvenile myositis (2004) (5)
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries (2021) (5)
The Czech version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (5)
OP0060 Efficacy and Safety of Tocilizumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Data from a Phase 3 Trial (2013) (5)
FRI0326 Effectiveness and safety of etanercept in paediatric subjects with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: The clipper study (2013) (5)
The Croatian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (4)
A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study (2014) (4)
Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis (2019) (4)
The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (4)
Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis (2011) (4)
OP0217 Adjudication of Infections in The Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (Pharmachild) Treated with Biologic Agents and/or Methotrexate (2016) (4)
Towards European harmonisation of healthcare for patients with rare immune disorders: outcome from the ERN RITA registries survey (2020) (4)
THE EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: 52-WEEK DATA FROM A PHASE 3 CLINICAL TRIAL (2012) (4)
Development and initial validation of the parent acceptable symptom state in juvenile idiopathic arthritis (JIA) (2008) (4)
Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study (2014) (4)
OP0007 Changes in Gene Expression and Inflammatory Proteins in Systemic Juvenile Idiopathic Arthritis Patients on Canakinumab Therapy (2014) (4)
FRI0528 Canakinumab in Systemic Juvenile Idiopathic Arthritis: Impact on the Rate and Clinical Presentation of Macrophage Activation Syndrome (2014) (4)
Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study (2020) (4)
The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (4)
The Chilean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (4)
The Austrian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (4)
Is minimal clinically important difference relevant for the interpretation of clinical trials in pediatric rheumatic diseases? (2007) (4)
American College of Rheumatology / European League Against Rheumatism Criteria for Minimal , Moderate , and Major Clinical Response in Adult Dermatomyositis and Polymyositis (2017) (4)
The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (4)
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation (Annals of the Rheumatic Diseases (2010) 69, (790-797)) (2011) (4)
A11: Assessment of Radiographic Progression in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2‐Year Data From CHERISH (2014) (3)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two (2017) (3)
Outcome Scores in Pediatric Rheumatology (2021) (3)
PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis (2013) (3)
Myositis response criteria methodology. (2015) (3)
Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease. (2010) (3)
The Georgian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (3)
The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (3)
FRI0336 Comparison of construct validity of two functional ability measures in children with juvenile dermatomyositis (2013) (3)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two (2017) (3)
Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: 2-year data from a phase 3 clinical trial (2014) (3)
Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data (2012) (3)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two (2017) (3)
Classification Criteria and Diagnostic Tests for Vasculitides (2012) (3)
Persistence of disease flares is associated to an inadequate colchicine dose in Familial Mediterranean Fever: a national multicentre longitudinal study. (2021) (3)
Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (2021) (3)
Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis (2014) (3)
The Latvian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (3)
Performing trials in children with rheumatic diseases: comment on the editorial by Lehman. (2008) (3)
Canakinumab In The Treatment Of Systemic Juvenile Idiopathic Arthritis: Results From a 12-Week Pooled Post-Hoc Analysis For Efficacy (2013) (3)
Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data (2014) (3)
Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: 2-year data from the CHERISH study (2014) (2)
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (2)
Clinically Meaningful Improvements in Health-Related Quality of Lite, Pain and Sleep Quality in Children with Polyarticular Juvenile Idiopathic Arthritis Treated with Abatacept over the Long Term (2011) (2)
A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2‐Year Results From the TENDER Trial (2014) (2)
THU0503 Identification of optimal subcutaneous (SC) doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis (PCJIA) (2017) (2)
FRI0496 Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis with and Without Fever (2015) (2)
OP0180 Maintenance of Efficacy by Canakinumab Treatment in Systemic Juvenile Idiopathic Arthritis Patients (2014) (2)
PReS-FINAL-2335: Preliminary analysis of 85 patients with mevalonate kinase deficiency from the eurofever registry (2013) (2)
The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (2)
PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA) (2013) (2)
Functional Ability and Health‐Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis (2020) (2)
AB1182 Efficacy and safety of canakinumab, fully human anti-interleukin-1beta antibody, in systemic juvenile idiopathic arthritis (2013) (2)
Preliminary validation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 403 clinic patients (2008) (2)
Development of New Juvenile Arthritis Disease Activity Score Cut-Offs for Oligoarthritis and RF-Negative Polyarthritis from a Large Multinational Cohort of Children with Juvenile Idiopathic Arthritis (2017) (2)
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry (2022) (2)
A COMPARISON OF THE OUTCOME OF ADOLESCENT-AND ADULT-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (2013) (2)
Health related quality of life of patients with juvenile dermatomyositis. The printo multinational quality of life cohort study. (2006) (2)
PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study (2013) (2)
LB0004 EFFICACY AND SAFETY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS AND JUVENILE PSORIATIC ARTHRITIS: PRIMARY RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA) (2021) (2)
Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism unfractionated heparin for the prophylaxis of venous thromboembolism in elective hlp replacement (1999) (2)
Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis (2020) (2)
A52: The Impact of Adalimumab on Growth in Patients With Juvenile Idiopathic Arthritis (2014) (2)
The Slovak version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (2)
OP0056 MAINTENANCE OF CLINICAL RESPONSE IN INDIVIDUAL CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH SUBCUTANEOUS ABATACEPT (2019) (2)
The Bulgarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). (2001) (2)
“To Randomize, or Not to Randomize, That is the Question” (2021) (2)
Determinants of Discordance Between Criteria for Inactive Disease and Low Disease Activity in Juvenile Idiopathic Arthritis (2020) (2)
THU0525 Safety of adalimumab ± methotrexate for the treatment of polyarticular juvenile idiopathic arthritis (PJIA): strive registry (2017) (2)
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (2)
Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever (2015) (2)
Publisher Correction: Biological classification of childhood arthritis: roadmap to a molecular nomenclature (2021) (1)
An Open-Label Extension Study to Assess the Long-Term Safety and Clinical Benefit of Etanercept on Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: A 4-Year Update (2015) (1)
Poster Session III (PIII 1–97) Displayed 7:00 am – 11:00 am Attended 7:00 am – 8:00 am (2013) (1)
The Eurofever Registry for autoinflammatory diseases: results of the first 15 months of enrolment (2011) (1)
A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis (2014) (1)
Behçet disease in the pediatric age: data on 129 patients collected from an Italian cohort (2016) (1)
Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data (2014) (1)
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (1)
The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (1)
Biologic Response Modifiers in Pediatric Rheumatology (2017) (1)
289. Assessment of Radiographic Progression in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Tocilizumab: 2-Year Results from the Tender Trial (2014) (1)
PReS-FINAL-2011: Preliminary validation of a new hybrid measure of muscle strength for juvenile dermatomyositis (2013) (1)
Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept (2008) (1)
The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (1)
The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (1)
THU0508 Safety and Efficacy of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: 5-Year Data from Tender, A Phase 3 Clinical Trial (2015) (1)
The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (1)
THU0666 SERIOUS/AT LEAST MODERATE INFECTIONS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS ON SYNTHETIC AND BIOLOGIC DRUGS FROM THE PHARMACHILD REGISTRY (2019) (1)
THU0579 Treating To Target with Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis: Results from The Long-Term Extension The Phase III Pivotal Trial (2016) (1)
PRK7 PATIENTS ARE SATISFIED WITH TELEMEDICINE (HOME-CARE) (2002) (1)
THU0517 THE LONGITUDINAL EUROFEVER PROJECT: AN UPDATE ON ENROLLMENT (2019) (1)
BHPR research: qualitative1. Complex reasoning determines patients’ perception of outcome following foot surgery in rheumatoid arhtritis (2012) (1)
A30: Assessment of Construct and Discriminative Validity of the 3‐Variable JADAS in Relation of Parent‐Reported Outcomes (2014) (1)
THU0477 Canakinumab Improves Health-Related Quality of Life (HRQOL) and Daily Functioning in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients (2013) (1)
Correction to: A national cohort study on pediatric Behçet’s disease: cross-sectional data from an Italian registry (2018) (1)
OP0107 Clinical features at presentation in a series of 86 patients with genetically confirmed traps and 33 patients with inflammatory symptoms and the r92q variant from the eurofevers/eurotraps registry (2013) (1)
OP0185 Efficacy of Canakinumab in Biologic NaÏVe versus Previously Biologic-Exposed SJIA Patients (2014) (1)
PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH (2013) (1)
OP0062 The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Serious Adverse Events. The 5882 Pharmachild Cohort (2015) (1)
Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients (2014) (1)
Principles of management of juvenile idiopathic arthritis (2013) (1)
OP0273 ADHERENCE TO COLCHICINE TREATMENT AND COLCHICINE RESISTANCE IN A MULTICENTRIC FMF NATIONAL COHORT (2020) (1)
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients (2013) (1)
FRI0502 Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis (2015) (1)
OP0136 Baseline Characteristics of Patients with Active Systemic JIA Successfully Discontinuing Corticosteroid while Receiving Canakinumab: Secondary Analysis from a Pivotal Phase 3 Trial (2013) (1)
OP0058 DEVELOPMENT OF INFLAMMATORY BOWEL DISEASE DURING TREATMENT WITH ETANERCEPT IN PATIENTSWITH JUVENILE IDIOPATHIC ARTHRITIS (2019) (1)
Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (1)
A169: Cumulative Long‐Term Safety, Efficacy and Patient‐Reported Outcomes in Children With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept: Up to 7 Years of Treatment (2014) (1)
Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS) (2008) (1)
Development and External Validation of a Model Predicting New‐Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis (2022) (1)
PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis (2013) (1)
The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (1)
Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis? (2014) (1)
Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries (2014) (1)
Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis (2011) (1)
OR13-004 – Evidence-based clinical classification criteria for periodic fevers (2013) (1)
Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset (2014) (1)
SAT0515 GROWTH AND DEVELOPMENT OF PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH SUBCUTANEOUS ABATACEPT (2019) (1)
PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis (2013) (1)
O53. Efficacy and Safety of Tocilizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: 2 Year Data from Cherish (2014) (1)
SAT0483 Tapering and Withdrawal of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results from an Alternative Dosing Regimen in the Tender Study (2015) (1)
Corrigendum to The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort. (2022) (1)
The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (1)
OP0181 Treating to Target of Minimal Disease Activity and Normal Function in Polyarticular Juvenile Idiopathic Arthritis with Adalimumab: Analysis from A Phase 3 Clinical Trial (2014) (1)
THU0515 PAIN IS THE MAIN DETERMINANT OF WELL-BEING IN OLIGO- AND POLYARTICULAR JIA: EVIDENCE FROM THE PHARMACHILD REGISTRY (2019) (1)
A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials (2011) (1)
Long-term follow-up of systemic onset juvenile idiopathic arthritis patients treated with Anakinra (2011) (1)
Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients (2008) (1)
THU0216 Safety and Effectiveness of Adalimumabmethotrexate for The Treatment of Polyarticular Juvenile Idiopathic Arthritis (PJIA): Strive Registry (2016) (1)
Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial (2014) (1)
THU0516 LONG-TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB ADMINISTRATION IN SYSTEMIC AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (2019) (1)
FRI0547 DEVELOPMENT AND INITIAL VALIDATION OF THE SYSTEMIC JADAS, A NEW COMPOSITE DISEASE ACTIVITY SCORE FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (2019) (1)
Are withdrawal trials in paediatric rheumatic disease helpful (2008) (1)
SAT0470 Efficacy of Biologic Treatments in Juvenile Idiopathic Arthritis with a Polyarticular Course: An Indirect Comparison (2013) (1)
PW02-007 - The Eurofever registry: 3 years of enrollment (2013) (1)
JIA affected sibling pairs present high correlation for ANA and ILAR category (2011) (1)
Approaches to SARS-CoV-2 and other vaccinations in children with a history of multisystem inflammatory syndrome (MIS-C): An international survey (2022) (1)
OP0058 Improvement in patient-reported outcomes in patients with polyarticular-course juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease-modifying antirheumatic drugs treated with sc abatacept (2017) (1)
SAT0438 Catch-Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial (2013) (1)
Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry (2022) (1)
Paediatric rheumatologists do not score the physician's global assessment of juvenile idiopathic arthritis disease activity in the same way. (2023) (1)
The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (1)
PW02-005 - A web registry of genotype-phenotype correlation (2013) (1)
PReS-FINAL-2132: Defining criteria for high disease activity in juvenile idiopathic arthritis: definition and validation of juvenile arthritis disease activity score cutoffs (2013) (1)
PReS-FINAL-2329: Validation of the autoinflammatory activity index (AIDAI) (2013) (0)
Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients (2014) (0)
The paediatric rule (2017) (0)
SAT0446 A Meta-Analysis to Assess the “Real” Placebo Effect in Juvenile Idiopathic Arthritis (JIA) (2013) (0)
Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis (2021) (0)
The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
Needs in paediatric Rheumatology: The PRINTO perspective (2010) (0)
Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the “comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS” (STARS) trial (2022) (0)
LB0002 BARICITINIB IN JUVENILE IDIOPATHIC ARTHRITIS: A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, WITHDRAWAL, EFFICACY AND SAFETY STUDY (2022) (0)
Investigating the use of a limited core outcome variable set for the classification of response following methotrexate treatment in juvenile idiopathic arthritis (JIA) (2008) (0)
SP0112 Current Evidence for the Treatment of Juvenile Dermatomyositis (2015) (0)
The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
trials in pediatric rheumatic diseases? Is minimal clinically important difference relevant for the interpretation of clinical (2017) (0)
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
Correction: 2016 American college of rheumatology/European league against rheumatism criteria for minimal moderate, and major clinical response in juvenile dermatomyositis (2018) (0)
THU0215 Long-Term Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA): 5-Year Follow-up of An Open-Label Trial (2016) (0)
The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
FRI0571 MEASUREMENT PERFORMANCE OF REDUCED VERSIONS OF MUSCLE STRENGTH TOOLS IN JUVENILE DERMATOMYOSITIS (2019) (0)
Reply to letter by Isenberg and Gordon commenting on the Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus. (2006) (0)
The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
Paediatric rheumatology Performance of the Birmingham Vasculitis Activity Score and Disease Extent Index in childhood vasculitides (2012) (0)
Paediatric rheumatology Performance of the Birmingham Vasculitis Activity Score and Disease Extent Index in childhood vasculitides (2012) (0)
The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
Arthritis Development and Testing of Reduced Joint Counts in Juvenile Idiopathic and for the Pediatric Rheumatology International Trials Organization (2008) (0)
OP0103 Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis (2018) (0)
The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis (2022) (0)
Reply to the Letter to the Editor by Kimura et al "Response to Editorial Accompanying STOP-JIA Articles by Ruperto, et al". (2021) (0)
The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
THU0549 Absence of association between drug exposure and infection in patients with polyarticular-course juvenile idiopathic arthritis and inadequate response to biologic or non-biologic dmards treated with sc and iv abatacept (2018) (0)
O28.â€ƒSUBCUTANEOUS ABATACEPT IN PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC OR NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: PHARMACOKINETICS, EFFICACY AND SAFETY (2017) (0)
PW02-022 - Recurrent fever syndromes: multiple gene mutations (2013) (0)
The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study (2022) (0)
POS1330 SAFETY OF ANAKINRA IN PATIENTS WITH CRYOPYRIN ASSOCIATED PERIODIC SYNDROMES (CAPS) USING A GRADUATED PRE-FILLED SYRINGE (2021) (0)
The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
ANTINUCLEAR ANTIBODY POSITIVITY IS THE BEST PREDICTOR OF RESPONSE TO METHOTREXATE IN JUVENILE IDIOPATHIC ARTHRITIS. ANALYSIS OF THE PRINTO TRIAL: 39 (2006) (0)
The PRINTO juvenile dermatomyositis trial – Authors' reply (2016) (0)
The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
Response to: ‘Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?’ by Fayand et al (2020) (0)
The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
Validity and Reliability of Four Parent/Patient–Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring (2022) (0)
SAT0524B THE HETEROGENEITY OF JUVENILE PSORIATIC ARTHRITIS: EVIDENCE FROM A LARGE MULTINATIONAL COHORT (2019) (0)
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study. (2022) (0)
Current evidence for the medical treatments of systemic juvenile idiopathic arthritis (2014) (0)
277. Growth During Tocilizumab Therapy in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data from the Phase III Cherish Trial (2015) (0)
A171: Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight (2014) (0)
Investigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with methotrexate (MTX) (2008) (0)
OP0164 LONG-TERM SAFETY OF ANAKINRA IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS FROM THE PHARMACHILD REGISTRY (2021) (0)
The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
PROMs for Juvenile Idiopathic Arthritis (2016) (0)
The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
OP0258 LESSON FROM EUROFEVER REGISTRY AFTER THE FIRST TEN YEARS OF ENROLLMENT (2019) (0)
OP0182 A Pharmacometric-Based Analysis Indicated NO Relationship between Occurrence of Safety Events and Canakinumab Exposure in Systemic Juvenile Idiopathic Arthritis Patients (2014) (0)
06. Identification of optimal subcutaneous doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis (2017) (0)
Emerging therapies for juvenile arthritis: agents in early clinical trials (2022) (0)
THU0210 The comparison of childhood polyarteritis nodosa and cutaneous polyarteritis NODOSA (2013) (0)
Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review (2023) (0)
Biologics in paediatric rheumatic diseases (2016) (0)
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis. (2023) (0)
PReS-FINAL-2070: Efficacy of biologic treatments in juvenile idiopathic arthritis with a polyarticular course: an indirect comparison (2013) (0)
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles. (2023) (0)
The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
SAT0578 TOWARDS EUROPEAN HARMONISATION OF HEALT CARE FOR PATIENTS WITH RARE IMMUNE DISORDERS: ERN RITA RESULT FROM THE REGISTRIES SURVEY (2019) (0)
Evaluation of the power of six clustering features in identifying a homogeneous disease subset in juvenile idiopathic arthritis (JIA) (2008) (0)
Tofacitinib for juvenile idiopathic arthritis – Authors' reply (2022) (0)
The effects of infliximab plus methotrexate therapy on the modulation of inflammatory disease markers in patients with juvenile rheumatoid arthritis (2005) (0)
Validation of Flare Criteria for Children and Adolescents with Systemic Lupus Erythematosus (2017) (0)
FRI0543 EFFICACY AND SAFETY OF INTRAVENOUS GOLIMUMAB IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM A PHASE 3 OPEN-LABEL STUDY (2019) (0)
Sorafenib in Advanced Hepatocellular Carcinoma (2008) (0)
AB0984 Development of a Juvenile Systemic Sclerosis Response Index (JSSRI) (2015) (0)
FRI0572 DISABILITY AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL (2019) (0)
Validation of Clinically Relevant Improvement in Children and Adolescents with cSLE (2017) (0)
Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: Findings from an open-label treatment extension (Annals of the Rheumatic Diseases (2010) 69, 3 (585-587)) (2012) (0)
Some clarifications on the new classification criteria for recurrent fevers. (2020) (0)
FRI0537 LONG-TERM OUTCOMES AND TREATMENT EFFICACY IN PATIENTS WITH TNF RECEPTOR-ASSOCIATED AUTOINFLAMMATORY SYNDROME (TRAPS): A SERIES OF 290 CASES FROM THE EUROFEVER/EUROTRAPS INTERNATIONAL REGISTRY (2019) (0)
Performance of the 2016 ACR-EULAR myositis response criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles. (2023) (0)
POS0334 DRIVERS OF NON-ZERO PHYSICIAN GLOBAL SCORES DURING PERIODS OF INACTIVE DISEASE IN JUVENILE IDIOPATHIC ARTHRITIS (2022) (0)
SP0021 DELIVERING FUTURE GLOBAL RESEARCH CHALLENGES IN PAEDIATRIC RHEUMATOLOGY (2019) (0)
The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry (2023) (0)
Predictors of Clinical Remission With Etanercept in Paediatric Patients With Extended Oligoarticular, Enthesitis-Related Arthritis and Psoriatic Arthritis : Findings From the CLIPPER Study (2016) (0)
Reply (2011) (0)
OP0135 Clinical and therapeutic features of 270 patients with macrophage activation syndrome enrolled in a multinational survey (2013) (0)
SP0153 How to obtain consent from children and their families (2013) (0)
The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
AB1072B THE CONSEQUENCES OF THE PROVISIONAL PAEDIATRIC RHEUMATOLOGY INTERNATIONAL TRIALS ORGANISATION JUVENILE IDIOPATHIC ARTHRITIS CLASSIFICATION CRITERIA (2019) (0)
The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
SAT0669 DISCRIMINANT ABILITY OF THE PARENT VERSION OF THE JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE IN A LARGE MULTINATION COHORT OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (2019) (0)
SP0069 JIA and Other Paediatric Rheumatic Diseases (2016) (0)
Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: Multicenter international study. (2023) (0)
The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
SP0063 Clinical Trial Design in Pediatric Rheumatology (2016) (0)
Does the perception of health related quality of life (hrql) in children with juvenile idiopathic arthritis (JIA) change among different cultures (2005) (0)
The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (0)
FRI0534 Physical Activity, Overweight, and Leisure Time Activity in a Cohort of Juvenile Idiopathic Arthritis Patients (2015) (0)
The Eurofever Project: towards the longitudinal stage (2015) (0)
PRINTO-projects: Past, present and future (2003) (0)
A new approach to defining inactive disease, minimal disease activity and parent- and child-acceptable symptom state in juvenile idiopathic arthritis (2011) (0)
170 Safety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis (2019) (0)
PReS13-SPK-1576: Unmeet needs in JIA treatment (2013) (0)
SAT0386 Adjudication of infections from the pharmacovigilance in juvenile idiopathic arthritis patients (PHARMACHILD) treated with biologic agents and/or methotrexate: update on results with a focus on opportunistic infections (2018) (0)
PReS-FINAL-2102: Comparison of sensitivity and specificity of MAS and HLH diagnostic guidelines in 362 children with MAS complicating systemic JIA (2013) (0)
PReS-FINAL-2129: Whole-body versus localized magnetic resonance imaging in the assessment of juvenile dermatomyositis (2013) (0)
OP0340 Evidence based recommendations for corticosteroid tapering/discontinuation in new onset juvenile dermatomyositis patients from the printo trial (2018) (0)
Demographic and Genetic Results From the EUROFEVERS/EUROTRAPS Consortia in the Largest Series of Patients with TRAPS Yet Reported (2011) (0)
PReS-FINAL-2337: The eurofever registry: 3 years of enrollment (2013) (0)
SAT0455 Preliminary Validation of a New Hybrid Measure of Muscle Strength for Juvenile Dermatomyositis (2013) (0)
SAT0486 Macrophage Activation Syndrome and Familial Hemophagocytic Lymphohistiocytosis: Is Their Clinical Phenotype Really Similar? (2015) (0)
7.4 Improvements in individual disease components are sustained with long-term adalimumab therapy for polyarticular Juvenile Idiopathic Arthritis (2008) (0)
POS1372 THE 2021 EULAR AND ACR POINTS TO CONSIDER FOR DIAGNOSIS, MANAGEMENT AND MONITORING OF THE IL 1 MEDIATED AUTOINFLAMMATORY DISEASES: CAPS, TRAPS, MKD, AND DIRA (2022) (0)
Trial Design and Collaborative Work in Pediatric Rheumatology (2017) (0)
PW02-008 - TRAPS in the real world: an international registry (2013) (0)
PW02-037 - The Eurofever cohort of 136 patients with CAPS (2013) (0)
ORAL PRESENTATION OF ABSTRACTS PAEDIATRIC AND ADOLESCENT ORAL ABSTRACTS (2016) (0)
SP0163 Switching Measures on the Transition to Adulthood (2013) (0)
PW01-026 – Validation of pediatric diagnostic criteria in FMF (2013) (0)
3.5 Comparison of functional ability in juvenile idiopathic arthritis, juvenile dermatomyositis, juvenile systemic lupus erythematosus and healthy controls. An analysis of the PRINTO database (2008) (0)
IMACS and ACR JDM Working Group Joint Breakfast Meeting (2005) (0)
Pediatric rheumatology Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study (2006) (0)
PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy (2013) (0)
FRI0457 LONG-TERM OUTCOMES AND TREATMENT EFFICACY IN PATIENTS WITH TNF RECEPTOR-ASSOCIATED AUTOINFLAMMATORY SYNDROME (TRAPS) FROM THE EUROFEVER INTERNATIONAL REGISTRY (2020) (0)
Share – Workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile idiopathic arthritis (2014) (0)
Oral Session II‐A (OII‐A) (2011) (0)
Therapeutic approaches for the treatment of new onset and flared juvenile systemic lupus erythematosus with active renal disease: an international multicenter PRINTO study (2011) (0)
Therapy of autoinflammatory diseases: results from an international registry (2011) (0)
An international survey in 29 countries on health related quality of life (HRQOL) in Juvenile Idiopathic Arthritis (JIA). Part II: A generic instrument: The Child Health Questionnaire (CHQ) (2000) (0)
PReS-FINAL-2141: Clinical features, therapeutic interventions and outcome of 362 patients with macrophage activation syndrome enrolled in a multinational survey (2013) (0)
OP0292 HIGH EFFICACY OF CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) ACROSS AGE GROUPS: COMPARISON OF CHILDREN, ADOLESCENTS AND YOUNG ADULTS BASED ON POOLED CLINICAL TRIAL RESULTS (2020) (0)
OP0006 Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis (2014) (0)
Development and initial validation of a new short and simple Health-Related Quality Of Life (HRQL) Questionnaire for Pediatric Rheumatic Diseases (PRD) (2008) (0)
Network in pediatric rheumatology: the example of pediatric rheumatology international trials organisation. (2008) (0)
OP0065 Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis (2014) (0)
THU0497 MAINTENANCE OF MINIMAL DISEASE ACTIVITY OR INACTIVE DISEASE STATUS AND PATIENT-REPORTED OUTCOMES IN INDIVIDUAL PAEDIATRIC PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH SUBCUTANEOUS ABATACEPT (2020) (0)
The Eurofever project: an update on the longitudinal stage (2017) (0)
Prevalence of monogenic autoinflammatory diseases among Pediatric Rheumatology centers: the Eurofever PReS/PRINTO survey (2008) (0)
POS1293 TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS (2022) (0)
Concurrent Therapeutics PROSPECTIVEOPEN LABEL STUDY RA PATIENTS ANTI-TNF IN THE THE (2005) (0)
Growth and Puberty in Juvenile Dermatomyositis a Longitudinal Multinatinal Cohort Study (2017) (0)
POS0340 PREDICTORS OF CLINICAL RESPONSE TO ABATACEPT IN CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (2022) (0)
PReS-FINAL-2207: Results from a multicenter international registry of Familial Mediterranean Fever: validation of the new set of pediatric diagnostic criteria (2013) (0)
PReS-FINAL-2089: Temporomandibular joint involvement and quality of life in juvenile idiopathic arthritis (2013) (0)
PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients (2013) (0)
OP0215 WHAT DOES THE PATIENT WELL-BEING VAS TELL US WHEN THE PHYSICIAN GLOBAL ASSESSMENT SCORE IS ZERO? ANALYSIS OF A LARGE MULTINATIONAL DATASET (2022) (0)
SP0191 How to Deal with Methodology in Orphan Diseases (2013) (0)
OP0175 The eurofever registry for autoinflammatory disease: Update on enrollment after 2 years (2013) (0)
Comparison of the accuracy of different definitions of clinical remission (CR) and minimal disease activity (MDA) in juvenile idiopathic arthritis (JIA) (2008) (0)
FRI0330 Development of cut-off values for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score (JADAS) (2013) (0)
PReS-FINAL-2345: Frequency of radiographic damage and progression in individual joints in children with juvenile idiopathic arthritis (2013) (0)
PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial (2013) (0)
THE EUROFEVER REGISTRY FOR AUTOINFLAMMATORY DISEASE: UPDATE ON ENROLLMENT AFTER 2 YEARS (2013) (0)
POS0076 S100A8/A9 AND S100A12 AS POTENTIAL PREDICTIVE BIOMARKERS OF ABATACEPT RESPONSE IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (2021) (0)
THU0498 PATIENT-REPORTED TREATMENT BURDEN AND ITS IMPACT ON QUALITY OF LIFE IN JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM THE PHARMACHILD REGISTRY (2020) (0)
AB0972 DEVELOPMENT OF THE PARENT VERSION OF THE JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE CUT-OFFS FOR MODERATE AND HIGH DISEASE ACTIVITY STATES IN JUVENILE IDIOPATHIC ARTHRITIS IN A LARGE MULTINATIONAL PATIENT SAMPLE (2020) (0)
Dissecting the heterogeneity of macrophage activation syndrome (2014) (0)
How experts on Autoinflammatory diseases classify Periodic Fever, Aphthous stomatitis, Pharyngitis and Cervical Adenitis (PFAPA): preliminary results of the Eurofever Delphi survey (2015) (0)
SAT0505 PLUTO TRIAL OF INTRAVENOUS BELIMUMAB IN PAEDIATRIC PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (cSLE): PATIENT RESPONSES OVER TIME (2020) (0)
OR7-004 – Validation of AIDAI score (2013) (0)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three (2017) (0)
Disclosure statement: The authors have declared no conflicts of interest. 277. CHRONIC FOOT PROBLEMS IN PEOPLE WITH GOUT: AN OBSERVATIONAL STUDY IN PRIMARY CARE (2014) (0)
SAT0504 How Experts on Autoinflammatory Diseases Classify Inherited Periodic Fevers and Pfapa: Preliminary Results of the Eurofever Delphi Survey (2015) (0)
SAT0447 Preliminary Definition of Cutoffs for High Disease Activity Based on Original and Simplified Jadas in Juvenile Idiopathic Arthritis (2013) (0)
Share – Workpackage 4: addressing the need for health care for paediatric rheumatic diseases throughout europe (2014) (0)
Achieving consensus on quality indicators (QI) for pediatric Systemic Lupus Erythematosus (pSLE) (2011) (0)
POS0173 DATA-DRIVEN MRI DEFINITIONS FOR ACTIVE AND STRUCTURAL SACROILIAC JOINT LESIONS IN JUVENILE SPONDYLOARTHRITIS TYPICAL OF AXIAL DISEASE (2022) (0)
POS0169 OPEN-LABEL, LONG-TERM (10-YEAR) STUDY OF THE SAFETY OF ETANERCEPT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS (2022) (0)
Psychometric Evaluation of Korean Childhood Health Assessment Questionnaire For Clinical Research (2001) (0)
How experts on autoinflammatory diseases classify inherited periodic fevers: preliminary results of the Eurofever Delphi Survey (2015) (0)
PReS-FINAL-2194: Evidence-based clinical classification criteria for periodic fevers (2013) (0)
THU0334 Differences in the features of familial mediterranean fever among patients from europe as compared to those from the eastern mediterranean countries (2013) (0)
SP0063 Novel Therapeutic Approaches for Still’s Disease (2013) (0)
FRI0335 The Eurofever Project: Towards the Longitudinal Stage (2015) (0)
The importance of clinical trials for the paediatric rheumatic diseases: Organisation, methodological and ethical problems (2000) (0)
8.5 Predictors of long-term outcome of Juvenile Dermatomyositis (JDM): a Multicenter, Multinational Study of 490 patients (2008) (0)
THU0503 PLUTO TRIAL: SENSITIVITY ANALYSES OF SRI4 RESPONSE WITH BELIMUMAB VS PLACEBO IN PAEDIATRIC PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (CSLE) (2020) (0)
CS-10 Criteria for clinically relevant improvement in children & adolescents with childhood-onset systemic lupus erythematosus (2018) (0)
AB0879 Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Paediatric Patients from Two To Less than Eighteen Years of Age with Juvenile Idiopathic Arthritis (2016) (0)
O43 5-Year Data from Tender, a Phase III Clinical Trial: Safety and Efficacy of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (2016) (0)
The PRINTO provisional definition of remission in juvenile dermatomyositis (2011) (0)
PP11. Assessment of radiographic progression in patients with systemic juvenile idiopathic arthritis treated with tocilizumab: 2-year data from tender (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Nicolino Ruperto?

Nicolino Ruperto is affiliated with the following schools:

Nicolino Ruperto's Academic­Influence.com Rankings

Nicolino Ruperto's Degrees

Similar Degrees You Can Earn

Why Is Nicolino Ruperto Influential?

Nicolino Ruperto's Published Works

Published Works

What Schools Are Affiliated With Nicolino Ruperto?

Nicolino Ruperto's AcademicInfluence.com Rankings